Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts before Detrimental Terminal Sequence

Circulation

Volumn 109, Issue 15, 2004, Pages 1870-1876

  Bhakdi, Sucharit ^a,b   Torzewski, Michael ^a   Paprotka, Kerstin ^a   Schmitt, Steffen ^a   Barsoom, Hala ^a   Suriyaphol, Prapat ^a   Han, Shan Rui ^a   Lackner, Karl J ^a   Husmann, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Inst of Med Microbiol and Hygiene   (Germany)

Author keywords

Atherosclerosis; C reactive protein; Complement; Immune system; Lipoproteins

Indexed keywords

C REACTIVE PROTEIN; CATHEPSIN H; CHOLESTEROL ESTERASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C5A; LIPOPROTEIN; PLASMIN; PROTEINASE; PROTEINASE K; TRYPSIN;

ARTICLE; ATHEROGENESIS; COMPLEMENT ACTIVATION; ENZYME ACTIVITY; HEART PROTECTION; HEMOLYSIS; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; TERMINAL SEQUENCE;

ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL ESTERASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DRUG SYNERGISM; ENDOPEPTIDASES; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; LIPOPROTEINS, LDL;

EID: 1842779854     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000124228.08972.26     Document Type: Article

References (40)

1. Vlaicu R, Niculescu F, Rus HG, et al. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. 1985;57:163-177.
2. Seifert PS, Hugo F, Hansson GK, et al. Prelesional complement activation in experimental atherosclerosis: terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest. 1989;60:747-754.
3. Seifert PS, Hugo F, Tranum-Jensen J, et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med. 1990;172:547-557.
4. Schmiedt W, Kinscherf R, Deigner HP, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1790-1795.
5. Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105:3025-3031.
6. Patel S, Thelander EM, Hernandez M, et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun. 2001;286:164-170.
7. Bhakdi S. Complement and atherogenesis: the unknown connection. Ann Med. 1998;30:503-507.
8. Bhakdi S. Immunopathogenesis of atherosclerosis: the Mainz hypothesis [in German]. Dtsch Med Wochenschr. 2002;127:390-394.
9. Bhakdi S, Torzewski M, Klouche M, et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999;19:2348-2354.
10. Alving CR, Richards RL, Guirguis AA. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol. 1977;118:342-347.
11. Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions: demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol. 1984;114:201-208.
12. Kruth HS. Subendothelial accumulation of unesterified cholesterol: an early event in atherosclerotic lesion development. Atherosclerosis. 1985; 57:337-341.
13. Simionescu N, Vasile E, Lupu F, et al. Prelesional events in atherogenesis: accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986;123:109-125.
14. Chao FF, Amende LM, Blanchette-Mackie EJ, et al. Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol. 1988;131:73-83.
15. Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med. 1995;182:1959-1971.
16. Torzewski M, Klouche M, Hock J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369-378.
17. Berman S, Gewurz H, Mold C. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol. 1986; 136:1354-1359.
18. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42:23-30.
19. Lehr HA, Sagban TA, Ihling C, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation. 2001;104:914-920.
20. Klouche M, Gottschling S, Gerl V, et al. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1376-1385.
21. Young SG, Witztum JL, Casal DC, et al. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B: demonstration by a new monoclonal antibody. Arteriosclerosis. 1986;6:178-188.
22. Suriyaphol P, Fenske D, Zähringer U, et al. Enzymatically modified nonoxidized low-density lipoprotein induces interleukin-8 in human endothelial cells: role of free fatty acids. Circulation. 2002;106:2581-2587.
23. Wieland E, Dorweiler B, Bonitz U, et al. Complement activation by oxidatively modified low-density lipoproteins. Eur J Clin Invest. 1999; 29:835-841.
24. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I: consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol. 1974;112:2135-2147.
25. Bhakdi S, Roth M, Nürnberger W. A simple method for quantitative measurement of C3d in human plasma. J Immunol Methods. 1984;74: 79-86.
26. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res. 1994;73:1-19.
27. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20:1177-1178.
28. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
29. Han SR, Momeni A, Strach K, et al. Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:661-667.
30. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20: 2094-2099.
31. Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043-13048.
32. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194-1197.
33. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812.
34. Hazen SL, Chisolm GM. Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. Proc Natl Acad Sci U S A. 2002;99:12515-12517.
35. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
36. Mold C, Gewurz H. Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae. J Immunol. 1981;127:2089-2092.
37. Jarva H, Jokiranta TS, Hellwage J, et al. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol. 1999;163:3957-3962.
38. Gershov D, Kim SJ, Brot N, et al. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192: 1353-1363.
39. Chao FF, Blanchette-Mackie EJ, Tertov VV, et al. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J Biol Chem. 1992;267:4992-4998.
40. Taskinen S, Kovanen PT, Jarva H, et al. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J. 2002;367:403-412.